- Home
- SNDR vs ACAD Comparison
SNDR vs ACAD Comparison
Compare SNDR & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDR
- ACAD
- Stock Information
- Founded
- SNDR 1935
- ACAD 1993
- Country
- SNDR United States
- ACAD United States
- Employees
- SNDR N/A
- ACAD N/A
- Industry
- SNDR Trucking Freight/Courier Services
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- SNDR Industrials
- ACAD Health Care
- Exchange
- SNDR Nasdaq
- ACAD Nasdaq
- Market Cap
- SNDR 4.0B
- ACAD 3.9B
- IPO Year
- SNDR 2017
- ACAD 2004
- Fundamental
- Price
- SNDR $22.77
- ACAD $25.17
- Analyst Decision
- SNDR Buy
- ACAD Buy
- Analyst Count
- SNDR 15
- ACAD 21
- Target Price
- SNDR $26.27
- ACAD $29.00
- AVG Volume (30 Days)
- SNDR 1.0M
- ACAD 1.6M
- Earning Date
- SNDR 10-30-2025
- ACAD 11-05-2025
- Dividend Yield
- SNDR 1.69%
- ACAD N/A
- EPS Growth
- SNDR 0.60
- ACAD 98.53
- EPS
- SNDR 0.64
- ACAD 1.54
- Revenue
- SNDR $5,613,800,000.00
- ACAD $1,047,118,000.00
- Revenue This Year
- SNDR $10.27
- ACAD $14.12
- Revenue Next Year
- SNDR $4.78
- ACAD $11.80
- P/E Ratio
- SNDR $35.20
- ACAD $16.10
- Revenue Growth
- SNDR 5.46
- ACAD 12.69
- 52 Week Low
- SNDR $20.11
- ACAD $13.40
- 52 Week High
- SNDR $33.90
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- SNDR 57.09
- ACAD 66.30
- Support Level
- SNDR $20.59
- ACAD $22.81
- Resistance Level
- SNDR $22.57
- ACAD $23.98
- Average True Range (ATR)
- SNDR 0.65
- ACAD 0.97
- MACD
- SNDR 0.14
- ACAD 0.15
- Stochastic Oscillator
- SNDR 96.98
- ACAD 100.00
About SNDR Schneider National Inc.
Schneider National Inc is a provider of surface transportation and logistics solutions in North America. The Company offers truckload, intermodal, and logistics services to a diverse customer base throughout the continental United States, Canada, and Mexico. The company's segments include Truckload; Intermodal; Logistics and other. It generates maximum revenue from the Truckload segment.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.